Business

May 19, 2014 1:46 PM

Merck elects not to develop Chimerix's HIV drug

Merck has opted out of developing an HIV drug from Chimerix. The small Durham drug developer had sold Merck exclusive rights 2 years ago with a potential $151 million payoff, which won't happen now.

Related content

Comments

Videos

Today's Market

Nasdaq
Powered by Barchart

Editor's Choice Videos

Raleigh Top Jobs

View All Top Jobs